Multiple sclerosis: overview of orally administrated disease-modifying drugs. Do genetics influence the success of treatment?
Multiple sclerosis (MS) is the main cause of acquired neurological disability in the young people. In MS treatment, disease modifying therapies (DMTs) are essential to reduce disease progression by suppressing the inflammatory response responsible for promoting lesion formation. Injectable (Interfe...
Saved in:
Main Authors: | A. Ovčinikova, R. Kizlaitienė |
---|---|
Format: | Article |
Language: | English |
Published: |
Vilnius University Press
2019-03-01
|
Series: | Neurologijos seminarai |
Subjects: | |
Online Access: | https://www.journals.vu.lt/neurologijos_seminarai/article/view/27798 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Long-Term Safety and Effectiveness of Dimethyl Fumarate in Patients with Multiple Sclerosis Treated in Routine Medical Practice: Final Analysis of the ESTEEM Study
by: Krupa Shah Pandey, et al.
Published: (2024-12-01) -
TEC-ADHERE: Real-World Persistence and Adherence on Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis in the French OroSEP Patient-Support Program
by: Pierre Labauge, et al.
Published: (2024-11-01) -
Role of pattern and multifocal electroretinogram for macular evaluation in patients with multiple sclerosis treated with fingolimod
by: Randa H. Abdelgawad, et al.
Published: (2025-01-01) -
Dimethyl fumarate effects on paraquat-induced hepatotoxicity in mice via anti-oxidative, anti-inflammatory, and anti-apoptotic activities
by: Maryam Kavianinia, et al.
Published: (2025-01-01) -
Administration and Monitoring Burden of High-Efficacy Disease-Modifying Therapies for Multiple Sclerosis: A Delphi Consensus of Clinical Experts from Saudi Arabia
by: Seraj Makkawi, et al.
Published: (2025-01-01)